Invest between 750 000 - 4 500 000 EUR for Orphan Drug Discovery and Development faster through innovative most unprecedented speed, accuracy, diversity in silico methods and using the power of cutting-edge artificial intelligence (AI) for 30 new small molecule drugs of rare and ultra rare diseases by the end of 2030
Choose your investment plan and rare disease
Setup new biotechnology Company in preferred country with % ownership
Start Orphan Drug Discovery and Development (Phase Drug Discovery and Development + Pre-Clinical Studies) (Disease Indication; Target ID; Assay development; Hi Identification; Hit-to-Lead; In-vivo POC/Lead; Lead Optimization; Pre-Clinical) - 12 months
Registration Orphan Drug Designation applications in parallel by using the ‘common application’ for submissions to the European Medicines Agency (EMA) The FDA Office of Orphan Products Development (OOPD) and the US FDA Office of Orphan Products Development (OOPD) - 6 months
Registration of Orphan new drug candidates Intellectual Property (IP) - Patent through WIPO.INT - 18 months
Exit strategies: Next rounds Venture Capital (for Clinical phase I, II, III, Registration and Market) // M&A (Mergers and acquisitions) // Licensing deal // IPO (Initial Public Offer) - 12 months
Licensing, through a classical royalties-based agreement, the set of information and eventually the intellectual property, to a “profit” third party, will be a pharmaceutical or a biotech company.
In case an interested third party will not be identified, e.g. due to a very low prevalence of the specific disease, an alternative pathway consisting of a full development financed entirely by non profit money will be actively explored.